# Risankizumab

## Skyrizi 75mg/0.83mL pre-filled syringe

#### 本院臨採清單

| 藥品代碼       | ISKY                                                                                                                                                                                                                                                                               |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.                                                                                                                                                                                             |
| 用法用量       | SC， 150 mg at week 0 and week 4， followed by every 12 weeks.                                                                                                                                                                                                                     |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                       |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                       |
| 禁忌           | Specific contraindications have not been determined                                                                                                                                                                                                                                |
| 副作用         | Common Dermatologic: Injection site reaction (1.5% )， Tinea (1.1% ) Immunologic: Antibody development (24%% ) Neurologic: Headache (3.5% ) Respiratory: Upper respiratory infection (13% ) Other: Fatigue (2.5% ) Serious Immunologic: Infectious disease (22.1% )， Tuberculosis |
| 孕期用藥建議   | Uknown 沒有資料                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議 | Unknown 沒有資料                                                                                                                                                                                                                                                                   |

